Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients)

The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.

Inclusion Criteria:

• Written informed consent
• Male or female aged from 18 to 80 years old
• Acute adenoviral keratoconjunctivitis

Exclusion Criteria:

• Active ocular allergy
• Ocular herpès disease
• History of bacterial conjunctivitis / blepharoconjunctivitis within the last month before the inclusion visit